Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients

References

• Filippini, G., Brusaferri, F., Sibley, W.A., Citterio, A., Ciucci, G., Midgard, R., Candelise, L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane. Database Syst. Rev. 2000, 4, CD001331.
   Google Scholar
• Tumani, H. Corticosteroids and plasma exchange in multiple sclerosis. J. Neurol. 2008, 255 Suppl 6, 36–42.
   PubMedGoogle Scholar
• Rentzos, M., Nikolaou, C., Rombos, A., Evangelopoulos, M.E., Kararizou, E., Koutsis, G., Zoga, M., Dimitrakopoulos, A., Tsoutsou, A., Sfangos, C. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin. Neurol. Neurosurg. 2008, 110, 992–996.
   PubMed Web of Science ®Google Scholar
• Jalosinski, M., Karolczak, K., Mazurek, A., Glabinski, A. The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis. Acta Neurol. Scand. 2008, 118, 120–125.
   PubMed Web of Science ®Google Scholar
• Mirowska-Guzel, D.M., Kurowska, K., Skierski, J., Koronkiewicz, M., Wicha, W., Kruszewska, J., Czlonkowski, A., Czlonkowska, A. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. J. Neuroimmunol. 2006, 176, 134–140.
   PubMedGoogle Scholar
• Pitzalis, C., Sharrack, B., Gray, I.A., Lee, A., Hughes, R.A. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J. Neuroimmunol. 1997, 74, 62–68.
   PubMedGoogle Scholar
• Bartosik-Psujek, H., Stelmasiak, Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur. J. Neurol. 2005, 12, 49–54.
   PubMed Web of Science ®Google Scholar
• Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G., Schaper, F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374, 1–20.
   PubMed Web of Science ®Google Scholar
• Cannella, B., Raine, C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37, 424–435.
   PubMed Web of Science ®Google Scholar
• Woodroofe, M.N., Cuzner, M.L. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine. 1993, 5, 583–588.
   PubMed Web of Science ®Google Scholar
• Malmeström, C., Andersson, B.A., Haghighi, S., Lycke, J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J. Neuroimmunol. 2006, 175, 176–182.
   PubMed Web of Science ®Google Scholar
• Okuda, Y., Sakoda, S., Fujimura, H., Saeki, Y., Kishimoto, T., Yanagihara, T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1999, 101, 188–196.
   PubMedGoogle Scholar
• Okuda, Y., Sakoda, S., Saeki, Y., Kishimoto, T., Yanagihara, T. Enhancement of Th2 response in IL-6-deficient mice immunized with myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 2000, 105, 120–123.
   PubMedGoogle Scholar
• Schönrock, L.M., Gawlowski, G., Brück, W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci. Lett. 2000, 294, 45–48.
   PubMedGoogle Scholar
• Schulte-Herbrüggen, O., Nassenstein, C., Lommatzsch, M., Quarcoo, D., Renz, H., Braun, A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 2005, 160, 204–209.
   PubMed Web of Science ®Google Scholar
• Veldhuis, W.B., Floris, S., van der Meide P.H., Vos, I.M., de Vries, H.E., Dijkstra, C.D., Bär, P.R., Nicolay, K. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J. Cereb. Blood Flow Metab. 2003, 23, 1060–1069.
   PubMedGoogle Scholar
• Casilli, F., Bianchini, A., Gloaguen, I., Biordi, L., Alesse, E., Festuccia, C., Cavalieri, B., Strippoli, R., Cervellera, M.N., Di Bitondo, R., Ferretti, E., Mainiero, F., Bizzarri, C., Colotta, F., Bertini, R. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem. Pharmacol. 2005, 69, 385–394.
   PubMed Web of Science ®Google Scholar
• McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D., McFarland, H.F., Paty, D.W., Polman, C.H., Reingold, S.C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B.Y., Wolinsky,J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121–127.
   PubMed Web of Science ®Google Scholar
• Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L., Lublin, F.D., Metz, L.M., McFarland, H.F., O’Connor,P.W., Sandberg-Wollheim, M., Thompson, A.J., Weinshenker, B.G., Wolinsky, J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 2005, 58, 840–846.
   PubMed Web of Science ®Google Scholar
• Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33, 1444–1452.
   PubMed Web of Science ®Google Scholar
• Radonic, A., Thulke, S., Mackay, I.M., Landt, O., Siegert, W., Nitsche,A. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. 2004, 313, 856–862.
   PubMed Web of Science ®Google Scholar
• www.ambion.com/techlib/tb/tb_151.html.
   Google Scholar
• Giguère, S., Wilkie, B.N., Prescott, J.F. Modulation of cytokine response of pneumonic foals by virulent Rhodococcus equi. Infect. Immun. 1999, 67, 5041–5047.
   PubMedGoogle Scholar
• Lee, H.J., Lee, H.P., Ha, S.J., Byun, D.G., Kim, J.W. Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann. Allergy Asthma Immunol. 2000, 84, 553–558.
   PubMedGoogle Scholar
• Goodin, D.S., Frohman, E.M., Garmany, G.P. Jr, Halper, J., Likosky, W.H., Lublin, F.D., Silberberg, D.H., Stuart, W.H., van den Noort, S. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002, 58, 169–178.
   PubMed Web of Science ®Google Scholar
• Lund, B.T., Ashikian, N., Ta, H.Q., Chakryan, Y., Manoukian, K., Groshen, S., Gilmore, W., Cheema, G.S., Stohl, W., Burnett, M.E., Ko, D., Kachuck, N.J., Weiner, L.P. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J. Neuroimmunol. 2004, 155, 161–171.
   PubMed Web of Science ®Google Scholar
• Suzuki, S., Tanaka, K., Suzuki, N. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. J. Cereb. Blood Flow Metab. 2009, 29, 464–479.
   PubMed Web of Science ®Google Scholar
• Czlonkowska, A., Ciesielska, A., Gromadzka, G., Kurkowska-Jastrzebska, I. Gender differences in neurological disease: role of estrogens and cytokines. Endocrine. 2006, 29, 243–256.
   PubMedGoogle Scholar
• Pelfrey, C.M., Cotleur, A.C., Lee, J.C., Rudick, R.A. Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J. Neuroimmunol. 2002, 130, 211–223.
   PubMed Web of Science ®Google Scholar
• Bebo, B.F. Jr, Schuster, J.C., Vandenbark, A.A., Offner, H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J. Immunol. 1999, 162, 35–40.
   PubMed Web of Science ®Google Scholar
• Dalal, M., Kim, S., Voskuhl, R.R. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J. Immunol. 1997, 159, 3–6.
   PubMed Web of Science ®Google Scholar
• Jansson, L., Olsson, T., Holmdahl, R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J. Neuroimmunol. 1994, 53, 203–207.
   PubMedGoogle Scholar
• Sicotte, N., Pfieffer, P., Klutch, R., Odesa, S., Bouvier, S., Wu, J., Alger, J., Voskuhl, R.R. Treatment of women with multiple sclerosi using the pregnancy hormone stradiol: a pilot study. Neurology. 2001, 56(Suppl. 3), A75.
   Google Scholar
• Janele, D., Lang, T., Capellino, S., Cutolo, M., Da Silva, J.A., Straub,R.H. Effects of testosterone, 17beta-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann. N. Y. Acad. Sci. 2006, 1069, 168–182.
   PubMedGoogle Scholar